New Zealand Insulin Drugs and Devices Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The New Zealand insulin drugs and devices market is being reshaped by a single national funder. Pharmac chooses which insulins, pumps and consumables are subsidised, so supplier decisions and funding notices in 2025 and 2026 now move demand faster than clinical fashion does.

Three forces are shaping the market: a growing diabetes population, with a study reported on 24 January 2025 projecting 502,358 people by 2044; a shift from vials and human insulin towards analogue pens and pumps; and supply withdrawals, as Eli Lilly and Novo Nordisk retire older presentations.

On 11 April 2025 Pharmac decided to fund Ryzodeg from 1 May 2025. On 1 October 2026 funding for Medtronic MiniMed 770G consumables ended, leaving Tandem and YpsoPump as the two funded pump systems.

Key Market Trends and Insights

• Larger patient base: A study reported on 24 January 2025 counted 268,248 New Zealanders with diabetes and projected 502,358 by 2044, led by rapid growth among Pacific and Asian communities.
• Premix funding: Pharmac decided on 11 April 2025 to fund Ryzodeg from 1 May 2025, expecting about 8,000 users in the first year and protecting its price until 30 April 2028.
• Pump consolidation: Pharmac expects nearly 10,000 people on pumps with automated insulin delivery after five years, and ended MiniMed 770G consumable funding on 1 October 2026.
• Supply withdrawals: Eli Lilly is retiring four 10 ml insulin vials during 2026, and Novo Nordisk is ending three 3 ml penfills and pens by the end of 2026.

New Zealand Insulin Drugs and Devices Market Size and Forecast

The market is moving from human insulin and vials towards analogue pens, premixed co-formulations and automated delivery systems that link pumps with glucose sensors. Long-acting insulin leads in value because it underpins most treatment plans, while pens and pen needles remain the largest device group. Premixed insulin and insulin pumps advance fastest as funded access widens, and Type 1 Diabetes grows quickest as pump eligibility reaches more patients. Auckland remains the largest region on population and diabetes burden, and Waikato grows quickest as services expand outside the main centres. National tenders, supply withdrawals and pump consolidation point to a durable shift in product mix rather than a short cycle, even as price pressure on mature insulin brands persists.

Key Takeaways: New Zealand Insulin Drugs and Devices Market

A Growing Patient Pool Underpins Demand

Revenue is on course to rise by about 57% across the decade, from USD 88.00 million in 2025 to USD 137.97 million in 2035 at a 4.6% CAGR. About 268,248 people live with diabetes, and the projection of 502,358 by 2044 keeps insulin and device demand rising even under a fixed national budget.

Premix and Pump Systems Lead Growth

Long-Acting Insulin holds the largest share, but Premixed Insulin grows at an estimated 5.8% CAGR and Insulin Pumps and Consumables at an estimated 8.4% CAGR through 2035. Tandem and YpsoPump are now the only funded pump systems, and Pharmac funded MyLife YpsoPump Orbit Soft infusion sets from 1 August 2026.

Supply Withdrawals Force Brand Switching

Suppliers, not Pharmac, decided to retire several presentations, and prescribers must move patients to funded alternatives. The changes shift volume towards pens, analogues and premix co-formulations.

• Eli Lilly is retiring Humalog, Humulin NPH, Humulin 30/70 and Humulin R vials during 2026
• Novo Nordisk ends NovoMix 30 FlexPen, Actrapid Penfill and Protaphane Penfill by the end of 2026
• Pharmac moved TruSteel infusion sets to monthly dispensing from 1 June 2026

New Zealand Insulin Drugs and Devices Market Report Summary

Key Insight

Demand is shifting from human insulin and vials towards analogue pens, premixed products and funded pump systems. Auckland leads, and Waikato grows fastest as diabetes services widen.

Key Trends in the New Zealand Insulin Drugs and Devices Market

The New Zealand insulin drugs and devices market is being reshaped by funding changes for pumps, infusion set shortages, supplier withdrawals and the delisting of older premixed insulin.

October 2026 - Pharmac Ends Funding for Medtronic MiniMed 770G Consumables

• Pharmac stopped funding MiniMed 770G infusion sets and reservoirs on 1 October 2026, so remaining users needed a new funded pump or an exemption.
• Switching to Tandem or YpsoPump needs a new special authority, and the rule of one pump per four years is waived for Medtronic users.
• Funded pump demand now concentrates on two systems, which strengthens consumable volumes for their suppliers.

August 2026 - Pharmac Funds YpsoPump Orbit Soft Infusion Sets and Retires Dexcom G6

• MyLife YpsoPump Orbit Soft infusion sets became funded on 1 August 2026 in four sizes.
• A Pharmac notice dated 4 August 2026 said the Dexcom G6 sensor will be retired by early 2027, with G7 and FreeStyle Libre 3 Plus as replacements.
• More infusion set choice and sensor changes tighten the link between pump consumables and glucose monitoring.

June 2026 - Global TruSteel Infusion Set Shortage Moves Pump Users to Monthly Dispensing

• Pharmac said a global supply constraint affects all four funded TruSteel products and is likely to last through the rest of 2026.
• From 1 June 2026 TruSteel listings moved to monthly dispensing, and Pharmac advised keeping stock for priority patients.
• Autosoft sets for Tandem pumps, supplied by NZMS, are unaffected, which may speed a switch between consumable brands.

May 2026 - PenMix 30 Penfill Delisted After Stock Expires in April

• Pharmac delisted the PenMix 30 3 ml penfill from 1 May 2026, after remaining stock expired in April 2026.
• NovoMix 30 FlexPen is also due to be discontinued by December 2026, with Ryzodeg named as a funded alternative.
• The withdrawals push premixed users to a single funded co-formulation and remove older mix options.

Key Insight

Funding consolidation for pumps, infusion set shortages and the withdrawal of older presentations are the main structural forces, while supply security remains the main risk to continuity of care.

Recent Market Developments in the New Zealand Insulin Drugs and Devices Market

Recent developments, presented from the most recent, show pump supplier results, falling global insulin sales, the separation of MiniMed from Medtronic and the sale of a pump maker's diabetes business.

August 2026 - Tandem Reports Second-Quarter Sales of USD 254.6 Million and Starts Mobi Rollout Abroad

• Tandem said in its results dated 6 August 2026 that international sales rose 7% to USD 75.3 million.
• It shipped about 11,000 pumps outside the United States and began the international commercial rollout of Tandem Mobi.
• Tandem's t:slim X2 is one of the two funded pumps in New Zealand, so global product moves can reach local users.

August 2026 - Novo Nordisk Reports Lower First-Half Insulin Sales

• Novo Nordisk's report of 4 August 2026 showed insulin sales of DKK 24,586 million, down 7% at constant exchange rates.
• International Operations insulin fell 3%, though second-quarter growth there was led by Tresiba volumes.
• Declining global insulin prices and market share shifts support further portfolio pruning in smaller markets.

March 2026 - MiniMed Group Lists on Nasdaq in USD 560 Million Offering

• MiniMed priced 28 million shares at USD 20 each on 6 March 2026, with Medtronic keeping about 90% of the new company.
• The offering funds MiniMed Flex, a smaller pump than the MiniMed 780G, and a patch pump system slated for United States filing.
• New Zealand users of the older MiniMed 770G must change pumps, so the new products matter mainly for future funding rounds.

August 2025 - Ypsomed Completes Sale of Diabetes Care Business to TecMed

• Ypsomed announced on 4 August 2025 that the sale of its Diabetes Care business to TecMed AG was completed.
• The sale first announced in April 2025 leaves Ypsomed focused on self-injection systems such as autoinjectors and pens.
• YpsoPump supply for New Zealand patients continues under the mylife brand through the local distributor, Pharmaco.

Key Insight

Falling global insulin sales, pump maker results, the separation of MiniMed from Medtronic and a diabetes business sale show suppliers repositioning towards devices and automated delivery.

New Zealand Insulin Drugs and Devices Industry Segmentation

The Expert Market Research’s report on the New Zealand Insulin Drugs and Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Drug Type

• Rapid-Acting Insulin
• Long-Acting Insulin
• Premixed Insulin
• Human Insulin
• Others

Long-Acting Insulin leads on value, in our estimate, because basal analogues such as Tresiba underpin most treatment plans. Premixed Insulin grows fastest at an estimated 5.8% CAGR through 2035, after Pharmac decided on 11 April 2025 to fund Ryzodeg from 1 May 2025 for about 8,000 users in its first year. Rapid-Acting Insulin grows steadily, though Eli Lilly is retiring its Humalog 10 ml vial, with supply ending in July 2026. Human Insulin, covering Humulin and Actrapid, declines in share as Humulin R, NPH and 30/70 vials leave the market in 2026 and Actrapid and Protaphane penfills end by the close of 2026.

Market Breakup by Device Type

• Insulin Pens and Pen Needles
• Insulin Pumps and Consumables
• Syringes and Vial Devices
• Patches and Others
• Others

Insulin Pens and Pen Needles lead, in our estimate, because most analogue insulin is dispensed in pens, which Pharmac says are generally available at no cost from diabetes clinics. Insulin Pumps and Consumables grow fastest at an estimated 8.4% CAGR through 2035, as Tandem and YpsoPump become the only funded systems after 1 October 2026. Syringes and Vial Devices lose ground as 10 ml vials are withdrawn during 2026. Patches and Others, including emerging patch pumps such as the MiniMed Fit slated for United States filing in 2026, start from a small base.

Market Breakup by Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Others

Type 2 Diabetes leads on value, in our estimate, because it accounts for most of the 268,248 people with diabetes reported on 24 January 2025, and Ryzodeg was aimed mainly at them. Type 1 Diabetes grows fastest at an estimated 5.4% CAGR through 2035, since funded pumps and sensors are targeted at people with type 1 and some other forms of diabetes. Gestational Diabetes grows at 4.3% on higher maternal age and screening. Others include monogenic and pancreatic diabetes and grow at 3.9%, with demand sensitive to the supply withdrawals announced in 2026.

Market Breakup by Region

• Auckland
• Wellington
• Canterbury
• Waikato
• Others

Auckland dominates, in our estimate, as the largest population centre, with Pacific and Asian communities that the study reported on 24 January 2025 expects to see the sharpest rises in diabetes. It grows at an estimated 4.4% CAGR through 2035 from a large base. Waikato is the fastest-growing region at an estimated 5.1%, as services outside the main centres expand. Canterbury grows at 4.6%, Wellington at 4.5% and Others, covering Bay of Plenty, Otago and Northland, at 4.7%. Because Pharmac funds nationally, pump switching from 1 October 2026 affects every region.

Competitive Landscape in the New Zealand Insulin Drugs and Devices Market

Competition combines global insulin makers, pump and sensor suppliers and local distributors. Because Pharmac contracts nationally, entry barriers include tender success, funded listing, Medsafe approval, supply reliability and relationships with diabetes clinics and prescribers.

Novo Nordisk

Novo Nordisk, headquartered in Bagsvaerd, Denmark, supplies NovoRapid, Tresiba, Ryzodeg, Actrapid and Protaphane in New Zealand through Novo Nordisk Pharmaceuticals Ltd. Pharmac funded Ryzodeg 70/30 Penfill from 1 May 2025 at a listed price of NZ$80 for five cartridges. In its report of 4 August 2026 the group recorded lower insulin sales, and three of its 3 ml penfills and pens leave New Zealand by the end of 2026.

Eli Lilly

Eli Lilly, headquartered in Indianapolis, United States, supplies Humalog and Humulin insulins in New Zealand in vials and 3 ml penfills. Education bodies relayed that the company would stop selling Humulin R vials in early 2026 and Humalog, Humulin NPH and Humulin 30/70 vials by mid-2026, with Pharmac ending funding between November 2026 and February 2027. The 3 ml penfills remain available, so the brands stay present.

Tandem Diabetes Care

Tandem Diabetes Care, headquartered in San Diego, United States, makes the t:slim X2 and Mobi insulin pumps, supplied in New Zealand through NZMS and funded by Pharmac with Autosoft infusion sets. In its results dated 6 August 2026 it reported sales of USD 254.6 million and about 11,000 international pump shipments in the quarter. It also began the international rollout of Tandem Mobi.

Medtronic

Medtronic, headquartered in Dublin, Ireland, sells the MiniMed 770G pump in New Zealand through InterMed, and its pump business now sits in MiniMed Group, which listed on the Nasdaq in March 2026. Pharmac ended funding for MiniMed 770G consumables on 1 October 2026, so users are moving to Tandem or YpsoPump. Medtronic keeps about 90% of MiniMed and remains an active supplier to existing patients.

Other players operating in the New Zealand insulin drugs and devices market include Sanofi, mylife Diabetes Care, Dexcom, Abbott, and Pharmaco, alongside needle and syringe suppliers, hospital procurement partners, community pharmacies and independent diabetes device distributors serving clinics and patients across New Zealand.

Key Insight

Competition rests on national funding listings, supply reliability, pen and pump compatibility with glucose sensors, and clinic relationships rather than price alone, while withdrawals could reshape positions.